KNSA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 28, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 29, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Increased ARCALYST Revenue Guidance

Oct 27, 2026

8-K

Kiniksa Pharmaceuticals Appoints Ross Moat as President and Chief Operating Officer

Oct 22, 2026

8-K

Kiniksa Pharmaceuticals Reports Q2 2026 Financial Results and Increased ARCALYST Revenue Guidance

Jul 28, 2026

8-K

Kiniksa Pharmaceuticals International, plc Announces Results of 2026 Annual Meeting of Shareholders

May 29, 2026

8-K

Kiniksa Pharmaceuticals Enters into Deed of Waiver with Baker Bros. Advisors LP

May 26, 2026

8-K

Kiniksa Pharmaceuticals Announces Resignation of Chief Strategy Officer Eben Tessari

May 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

28,882,977 Class A Common Shares Offered by the Selling Shareholders

Jul 22, 2020

424B5

28,882,977 Class A Common Shares Offered by the Selling Shareholders

Jul 20, 2020

424B5

28,882,977 Class A Common Shares Offered by the Selling Shareholders

May 15, 2020

424B5

28,882,977 Class A Common Shares Offered by the Selling Shareholders

May 13, 2020

424B4

2,654,984 shares

Feb 1, 2019

424B4

8,477,777 Shares

May 24, 2018

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 24, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2025

S-3

$400,000,000 EFFECTIVE

Jun 28, 2024

S-8 POS

Registration

Jun 28, 2024

S-8 POS

Registration

Jun 28, 2024

S-8 POS

Registration

Jun 28, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 16, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 21, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Patel Sanj K (Reporting)

Nov 6, 2026

Patel Sanj K (Reporting)

Nov 3, 2026

Ragosa Mark (Reporting)

Nov 3, 2026

Paolini John F. (Reporting)

Nov 3, 2026

Moat Ross (Reporting)

Nov 3, 2026

Megna Michael R (Reporting)

Nov 3, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 5, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 5, 2024

CORRESP

Form CORRESP - Correspondence

Jul 2, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jul 2, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 1, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jan 2, 2024

Kiniksa Pharmaceuticals International, plc KNSA · SEC Filings